Subcutaneous trastuzumab: A review of its use in HER2-positive breast cancer

Targeted Oncology

Volumn 9, Issue 1, 2014, Pages 85-94

  Sanford, Mark ^a  

^a ADIS   (New Zealand)

Author keywords

HER 2 positive breast cancer; Patient preferences; Pharmacokinetics; Subcutaneous administration; Therapeutic efficacy; Tolerability; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; BREAST NEOPLASMS; EVALUATION STUDY; FEMALE; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84899565617     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0313-1     Document Type: Review

References (26)

1. WHO International Agency for Research on Cancer. GLOBOCAN 2008: estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. http://globocan.iarc.fr. Accessed 26 Nov 2013
2. Yeo W (2012) HER2-positive metastatic breast cancer: new agents on the horizon. Hong Kong J Radiol 15(4 Suppl):51-56
3. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51
4. Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70(2):215-239
5. McKeage K, PerryCM(2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62(1):209-243 (Pubitemid 34169431)
6. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. HERA study team. Lancet 369(9555):29-36 (Pubitemid 46039831)
7. Genentech, Inc (2013) Herceptin (trastuzumab) intravenous infusion; US prescribing information. http://accessdata.fda.gov/drugsatfda-docs/label/2013/ 103792s5250lbl.pdf. Accessed 14 Jan 2014
8. Roche Products Limited (2013) Herceptin (trastuzumab) 600 mg/5 mL solution for injection: UK summary of product characteristics. http://www.medicines.org.uk/emc/medicine/28179/SPC/ Herceptin+600+mg+5+ml+Solution+for+Injection/. Accessed 14 Jan 2014
9. Hamizi S, Freyer G, Bakrin N et al (2013) Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. Onco Targets Ther 6:89-94
10. Shpilberg O, Jackisch C (2013) Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 109(6):1556-1561
11. Bittner B, Richter WF, Hourcade-Potelleret F et al (2012) Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 62(9):401-409
12. Roche Products Limited (2013) Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer [media release]. www.roche.com/media/media-releases/med-cor-2013-09-02.htm
13. Ismael G, Hegg R, Muehlbauer S et al (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13(9):869-878
14. Wynne C, Harvey V, Schwabe C et al (2013) Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 53(2):192-201
15. Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C et al (2014) Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol. doi:10.1038/psp.2.13.63
16. Wynne CJ, Ellis-Pegler RB, Waaka DS et al (2013) Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemother Pharmacol 72(5):1079-1087
17. Pivot X, Gligorov J, Müller Vet al (2013) Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 14(10):962-970
18. Pivot X, Gligorov J, Müller Vet al Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive breast cancer: cohort 2 of the PrefHer study [abstract no. P4-12-11]. San Antonio Breast Cancer Symposium; 10-14 Dec 2013; San Antonio (TX)
19. Melichar B, Stroyakovskiy D, Ahn JS et al Pathological complete response to trastuzumab subcutaneous fixed-dose formulation in the HannaH study: subgroup analysis of patient demographics and tumor characteristics and influence of body weight (BW) and serum trough concentration (Ctrough) of trastuzumab [abstract no. 254PD]. 37th Annual Meeting of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna
20. Fallowfield L, Jenkins V, Kilkerr J et al Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study [abstract no. 1759/P719]. European Cancer Congress 2013; 27 Sep-1 Oct 2013; Amsterdam
21. Jackisch C, Dank M, Frasci G et al Additional safety results of HannaH: a phase III randomised, open-label, international study of the subcutaneous formulation of trastuzumab (H) in HER2-positive early breast cancer patients [abstract no. 271P]. 37th Annual Meeting of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna
22. Pivot X, Gligorov J, Müller V et al Subcutaneous injection of trastuzumab - analysis of administration time and injection site reactions [abstract no. 2616]. 37th Annual Meeting of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna
23. Gligorov J, Azim HA, Ataseven B et al Safeher: A study of assisted-and self-administered subcutaneous trastuzumab (H-SC) as adjuvant therapy in patients with early HER2-positive breast cancer (EBC) [abstract no. 315TiP]. 37th Annual Meeting of the European Society for Medical Oncology; Sep 28-Oct 2 2012; Vienna
24. De Cock E, Tao S, Urspruch A et al (2012) Potential time savings with trastuzumab subcutaneous (SC) injection versus trastuzumab intravenous (IV) infusion: results from interviews conducted as part of a time-and-motion study (T&M) across 17 sites [abstract no. RU2]. Value Health 15(7):A280
25. Samanta K, Moore L, Jones G et al (2012) Potential time and cost savings with herceptin (trastuzumab) subcutaneous (SC) injection versus herceptin intravenous (IV) infusion: results from three different english patient settings [abstract no. PCN39]. Value Health 15(7):A415
26. De Cock E, Knoop A, Jakobsen EH et al Manual injection of subcutaneous trastuzumab vs intravenous trastuzumab for HER2-positive breast cancer: a time-and-motion study [abstract no. 1955/P128]. European Cancer Congress 2013; 27 Sep-1 Oct 2013; Amsterdam